Study S000754

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05872620
Acronym: ATTAIN-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 1613
Start: 2023-06-05
Primary completion: 2025-08-08
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight; Type 2 Diabetes
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZGQ; OTHER:2022-502837-24-00; OTHER:U1111-1289-8799

Registered primary outcomes

Percent Change From Baseline in Body Weight [Baseline, Week 72]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001832	Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials. Horn DB, Obesity pillars	2026	Randomized trial	PMID 42577069 DOI	cites ClinicalTrials.gov:NCT05872620; registry reference DERIVED:42577069
R0007652	Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Horn DB, Lancet (London, England)	2026	Randomized trial	PMID 41275875 DOI	cites ClinicalTrials.gov:NCT05872620; registry reference DERIVED:41275875